Patent SG-11201809625R-A (SG)
Title: 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer
Inventor: BASTIAN JOLIE ANNE
IPC: C07D405/06
Filed: 2017-05-31
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111110111111111111111111111111111111011111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2017/213919 Al 14 December 2017 (14.12.2017) WIP0 I PCT (51) International Patent Classification: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, C07D 405/06 (2006.01) A61P 35/00 (2006.01) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, A61K 31/4045 (2006.01) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (21) International Application Number: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, PCT/US2017/035097 TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 31 May 2017 (31.05.2017) kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (25) Filing Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (26) Publication Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (30) Priority Data: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 62/348,457 10 June 2016 (10.06.2016) US TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). Declarations under Rule 4.17: (72) Inventors: BASTIAN, Jolie Anne; c/o ELI LILLY — as to applicant's entitlement to apply for and be granted a AND COMPANY, P.O. Box 6288, Indianapolis, Indi- patent (Rule 4.17(ii)) ana 46206-6288 (US). CHEN, Jiehao; c/o ELI LILLY — as to the applicant's entitlement to claim the priority of the — AND COMPANY, P.O. Box 6288, Indianapolis, Indiana earlier application (Rule 4.17(iii)) 46206-6288 (US). COHEN, Jeffrey Daniel; c/o ELI LIL- Published: LY AND COMPANY, P.O. Box 6288, Indianapolis, Indi- = — with international search report (Art. 21(3)) ana 46206-6288 (US). HENRY, James Robert; c/o ELI — with sequence listing part of description (Rule 5.2(a)) LILLY AND COMPANY, P.O. Box 6288, Indianapolis, In- _ diana 46206-6288 (US). MCMILLEN, William Thomas; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indi- anaoplis, Indiana 46206-6288 (US). REAMAN, Bradley = Earl; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). RUBIO, Almude- na; c/o ELI LILLY AND COMPANY, P.O. Box 6288, In- — = — dianapolis, Indiana 46206-6288 (US). SALL, Daniel Jon; = — c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indi- anapolis, Indiana 46206-6288 (US). ZHAO, Gaiying; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapo- lis, Indiana 46206-6288 (US). = = Agent: TUCKER, Tina M. et al.; ELI LILLY AND COM- (74) _ PANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 = (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = 1-1 (54) Title: 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER 01 1-1 (57) : The present invention relates to certain novel 2,3-dihydro-1H-indole corn- 01 R2a pounds, pharmaceutical compositions comprising the compounds, and methods of using the M 1-1 Ric 0 R2 compounds to treat cancer, more particularly for the treatment of cancer selected from the Ri b IN 11 N 1 . I 11 1.1 group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, col- orectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary R1 a N - R3 a peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid ei 0 cancer, 0 glioblastoma, non- Hodgkin's lymphoma, and Hodgkin's lymphoma. C